FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
The FDA approved Guardant Health's new Guardant360 Liquid CDx, the largest FDA-approved liquid biopsy panel with a 100x wider genomic footprint than its predecessor. The test integrates genomic and epigenomic insights from a single blood draw, offering several-fold increased sensitivity for ctDNA detection and faster results in as little as seven days.
Key figures
- Drug Name
- Guardant360 Liquid CDx
- Coverage lives
- 300 million
- Patient data points
- 1 million
- Turnaround time days
- 7
- Genomic footprint expansion
- 100x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.